Whether you've found traditional diets and workouts ineffective or are seeking a medically supervised solution, tirzepatide offers a promising option for significant weight loss
Data from the SUSTAIN and SCALE trials demonstrated that semaglutide therapy is associated with reductions in LDL cholesterol, total cholesterol, and triglycerides, alongside modest increases in HDL.[3,8] For patients already managing cardiovascular risk, this creates a meaningful opportunity: GLP-1-related lipid improvement may reduce or eliminate the need for statin therapy, but that conversation should be guided by lab data not assumptions
The problem with GLP-1 as a drug candidate had always been its half-life: less than two minutes in the bloodstream before the enzyme DPP-4 degrades it
Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory-shock patients
du Sert N P, Hurst V, Ahluwalia A, et al
These extended health benefits make GLP-1 therapy a first-line consideration for most patients seeking comprehensive metabolic improvement
